Philoinvestor β’ 78 implied HN points β’ 04 Apr 23
- Moderna has faced significant insider selling of stock by top executives, leading to questions about their management and future prospects.
- Despite recent success with COVID vaccine sales, Moderna is now facing a period of cash burn and uncertainty as they seek to pivot post-pandemic.
- Investors in Moderna are banking on the company's RNA-technology pipeline to potentially deliver groundbreaking solutions, but there is high risk involved.